Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of diseas...See more
Headquarters:
Australia
Company Type:
SME
Company size:
11-50 Employees
Address:
LEVEL 9, 31 QUEENS STREET; MELBOURNE, VICTORIA 3000, AU
LOW
spending power
